Vaccination for children: DGCI approves phase 2/3 trials of Biological E's Covid vaccine on 5-to-18-year-olds
The phase 2 and 3 clinical trials have been conducted as per approved protocol titled ''A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study to Evaluate Safety, Reactogenicity, Tolerability and Immunogenicity of Corbevax Vaccine in Children and Adolescents'', a source said.
The DCGI''s permission was given, based on the recommendations by the Subject Expert Committee (SEC) on COVID-19. Source: PTI